Aadi Bioscience, Inc., founded by Dr. Neil Desai, is a clinical stage biopharmaceutical company.
Location: United States, California, Los Angeles
Employees: 1-10
Total raised: $95.5M
Investors 6
| Date | Name | Website |
| - | Avoro Capi... | avorocapit... |
| - | OrbiMed | orbimed.co... |
| - | 3B Future ... | 3bfuturehe... |
| - | Vivo Capit... | vivocapita... |
| - | Helsinn In... | helsinninv... |
| - | Hermed Cap... | hermedcapi... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 10.10.2022 | - | $72.5M | - |
| 08.05.2017 | Series A | $23M | - |
Mentions in press and media 11
| Date | Title | Description |
| 08.05.2024 | Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update | Fully enrolled registration-intended PRECISION1 trial; two-thirds interim analysis planned for Q3 2024 FYARRO® sales of $5.4 million for Q1 2024, reflects distributor ordering patterns and fewer commercial patient initiations at the start o... |
| 26.03.2023 | Aadi Bioscience Presents Clinical Data from PRECISION 1 and AMPECT Trials at the Society of Gynecological Oncology (SGO) Annual Meeting on Women's Cancer | LOS ANGELES, March 26, 2023 /PRNewswire/ -- Aadi Bioscience, Inc. AADI, a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR path... |
| 10.10.2022 | Aadi Bioscience Announces $72.5 Million Equity Deal | - |
| 23.09.2022 | Aadi Biosciences Finds $72.5M In Private Placement | Los Angeles-based Aadio Biosciences, a public biopharmaceutical company focused on therapy for cancer, said on Thursday that it has raised $72.5M in a private placement equity financing. The company said it agreed to issue and sell an aggre... |
| 01.11.2021 | Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer | LOS ANGELES, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes,... |
| 01.11.2021 | Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer - Form 8-K | Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer LOS ANGELES, November 1, 2021 - Aadi Bioscience, Inc. ("Aadi") (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for gen... |
| 25.10.2021 | Aadi Bioscience : Appoints Loretta Itri as Chief Medical Officer | LOS ANGELES, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes,... |
| 22.10.2021 | Aadi Bioscience : Announces Publication of its Phase 2 Registrational (AMPECT) Trial of nab-Sirolimus in Patients with Malignant Perivascular Epithelioid Cell Tumors in the Journal of Clinical Oncolog... | LOS ANGELES, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes,... |
| 14.05.2018 | Aadi Bioscience Raises $23 Million | - |
| 08.05.2017 | Aadi Bioscience Closes $23M in Series A Funding | Aadi Bioscience, Inc., a Pacific Palisades, Calif.-based clinical stage biopharmaceutical company, completed a $23M Series A funding round. The round was led by Hermed Capital with participation from Celgene Corporation, Vivo Capital, Deche... |
Show more